Trial Profile
Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Pioglitazone (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Oct 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Feb 2021.
- 15 Oct 2020 Status changed from not yet recruiting to recruiting.
- 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.